Oxford BioDynamics is developing and commercialising epigenetic biomarker tests based on its proprietary EpiSwitch technology, with a focus on oncology and autoimmune disorders. Two blood tests are commercially available: EpiSwitch PSE (Prostate Screening test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test).
Oxford BioDynamics (OBD) employs 3D genomics to develop cutting-edge diagnostic tools that improve patient outcomes, facilitate personalised medicine, and enhance the precision of therapeutic interventions. At the core of OBD’s innovation is the EpiSwitch platform, which enables the identification of epigenetic biomarkers based on CCSs (Chromosome Conformation Signatures). These signatures provide insights into the three-dimensional structure of the genome and its regulatory mechanisms, offering a novel and powerful basis for developing diagnostic and prognostic tests. EpiSwitch CiRT (Checkpoint Inhibitor Response Test), predicts a patient’s response to cancer immunotherapy, and the PROWES registry study is underway to generate uptake and to support inclusion in key guidelines. EpiSwitch PSE, for prostate cancer, has recently been launched and is initially targeting the concierge medicine sector in the US. EpiSwitch NST (for colorectal cancer) and EpiSwitch SCB (for canine cancers) ready for partnering. Even modest penetration into these large markets, notably with EpiSwitch PSE, could be transformative for OBD.
| Symbol | Primary exchanges |
| OBD | AIM London |